Notable Friday Option Activity: ZBIO, TECH, OMER

Bio-Techne (TECH) options traded 10,193 contracts today, representing roughly 1.0 million underlying shares and about 55.3% of TECH's one‑month average daily trading volume; the January 16, 2026 $60 put accounted for 5,000 contracts (~500,000 shares). Omeros (OMER) saw 7,979 option contracts (~797,900 underlying shares), or ~54.8% of its one‑month ADV, led by 1,321 contracts in the December 19, 2025 $12 call (~132,100 shares).

Analysis

Market structure: The flow shows concentrated directional activity — 5,000 Jan‑16‑2026 $60 puts in TECH (~500k shares, ~55% ADV) and 1,321 Dec‑19‑2025 $12 calls in OMER (~132k shares, ~55% ADV). Direct winners are put buyers/hedgers in TECH and call holders in OMER; market‑making desks take short vega/gamma exposure and will delta‑hedge into the equities, adding near‑term selling pressure for TECH and buying support for OMER. This is a large idiosyncratic demand signal relative to ADV, not a sector‑wide reallocation yet.

Risk assessment: Tail risks are binary biotech events (FDA/clinical) and idiosyncratic corporate surprises for TECH (lab‑spend slowdown or accounting/contract revision) that could move shares >30% before Jan 2026 expiries. Timeline: immediate (days) — dealer gamma hedging can amplify moves; short (weeks/months) — earnings/FDA windows create volatility; long (quarters) — positioning may unwind as options decay. Hidden dependencies: trades could be part of collars/structured notes or block rebalances; if collateralized, forced unwinds can cascade.

Trade implications: Preferred direct plays are asymmetric option structures: for TECH, buy protection via limited‑risk put spreads into Jan‑2026 strikes; for OMER, buy Dec‑2025 call spreads to capture the apparent directional flow while capping premium. Consider a small relative‑value pair (long OMER call spread, short TECH exposure) to exploit opposing trader intent and to neutralize sector beta. Size trades modestly (1–3% portfolio per theme) and use disciplined premium stops (40% loss) and profit targets (100–200%+).

Contrarian angles: The market may misconstrue block puts as pure directional shorts when they can be hedges for long equity holders or part of a funding structure — that increases odds of an overshoot then mean reversion. Historical parallels: large option blocks prior to biotech catalysts often create transient liquidity‑driven moves that reverse after dealers unwind hedges. If TECH does not break below $60 within 30–60 days, downside premium may be mispriced and present a short‑vol opportunity for premium sellers.

Key Decisions for Investors

• Establish a limited 1–2% portfolio position: buy Jan‑16‑2026 TECH $60/$45 put spread (max risk = premium paid). Enter within 7 trading days, set stop if premium falls 40%, target 2.5–3x return or close at 50% of notional if TECH > $70.
• Establish a 1–2% portfolio position: buy Dec‑19‑2025 OMER $12/$18 call spread to capture directional flow with capped risk. Add second tranche only if OMER trades >$13.50 or IV falls >10% from entry (take profit at 100–200%+ or at expiry).
• Implement a 1% pair trade (relative value): long OMER Dec‑2025 $12/$18 call spread and short 1% notional TECH stock (or equivalent via synthetic short) to neutralize broad biotech beta. Close pair if spread P/L hits ±30% or if a confirmed binary catalyst (FDA/earnings) is scheduled within 14 days.
• Risk control: Trim overall biotech/tools exposure by 2–4% if implied volatility on TECH or OMER rises >20% from current levels or if either stock moves >25% intra‑month; monitor earnings/FDA calendars for both tickers over the next 60 days and size/remove positions ahead of binary events.